According to sources familiar with the situation, the private equity firm Carlyle Group Inc. (CG.O) has gone into exclusive discussions to purchase a controlling share in two medical device firms owned by Medtronic Plc for a price of more than $7 billion. Medtronic Plc manufactures the products in question.

It would signal the completion of Medtronic’s 12-month study of its patient monitoring and respiratory treatments businesses, which it also contemplated spinning off if a deal were to be achieved in the coming weeks. Medtronic is working to simplify its product range and place more of its attention on its higher-growth assets, such as its devices for the heart and diabetes.

According to the sources, the divisions of Medtronic that will be sold off will be transferred to a new company with Carlyle as the dominant shareholder. According to the sources, Medtronic would maintain a share in the newly formed firm equivalent to more than 35 percent of its total voting power.

The Carlyle Group’s acquisition of these Medtronic divisions is likely to have far-reaching repercussions because of the following reasons:

Consolidation of the Industry: This move highlights a wider consolidation trend within the medical device business as companies attempt to enhance their portfolios and pursue synergistic opportunities.

Acceleration of Innovation: The Carlyle Group and Medtronic’s combined resources have the potential to accelerate innovation in the medical technology sector. It is possible that this may result in the creation of ground-breaking goods and treatments that will be of use to people all over the world.

Expansion on a Global Scale: OThis established a global presence; they can capitalize on their international connections worldwide market share and make their wares available to a more extensive customer base.

The business world of medicine is keeping a close eye on the progress made toward this transaction’s completion. The coming together of The Carlyle Group and Medtronic divisions will likely result in the formation of a healthcare behemoth that will shake things up in the industry and establish new standards of excellence. This exclusive negotiation between The Carlyle Group and Medtronic entities has the possibility of ground-breaking advancements in the constantly shifting environment of business and healthcare.

It is really thrilling to think of the possibilities of innovation, market expansion, and enhanced healthcare results as a result of their coming together. Keep an eye out for moments as this game-changing transaction, which will reshape the landscape of the medical device sector, moves forward.

The sources stressed that a deal is not a sure thing and asked to remain anonymous because the topic is confidential. Both Medtronic and Carlyle have chosen not to comment.